Patients with such hormone receptor-positive breast cancers are typically treated with adjuvant anti-estrogen therapies such as tamoxifen or aromatase inhibitors (AIs) for 5-10 yrs after surgical removal of the primary tumor [1]. Here, CYP19A1 is linked to breast carcinoma.